Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия; 2ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия; 3ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия t.ostroumova3@gmail.com
Список исп. литературыСкрыть список 1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int 2. Garg P, Arora U, Kumar A, Wig N. The "post-COVID" syndrome: How deep is the damage? J Med Virol 2021; 93 (2): 673–4. DOI: 10.1002/jmv.26465 3. Callard F, Perego E. How and why patients made Long Covid. Soc Sci Med 2021; 268: 113426. DOI: 10.1016/j.socscimed.2020.113426 4. Greenhalgh T, Knight M, A'Court C et al. Management of post-acute covid-19 in primary care. BMJ 2020; 370: m3026. DOI: 10.1136/bmj.m3026 5. Lopez-Leon S, Wegman-Ostrosky T, Perelman C et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [Preprint] 2021: 2021.01.27.21250617. DOI: 10.1101/2021.01.27.21250617 6. Townsend L, Dowds J, O'Brien K et al. Persistent poor health post-COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc 2021. DOI: 10.1513/AnnalsATS.202009-1175OC 7. Townsend L, Dyer AH, Jones K et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One 2020; 15 (11): e0240784. DOI: 10.1371/journal.pone.0240784 8. Воробьева Ю.Д., Дюкова Г.М. Астенический синдром в контексте пандемии COVID‑19. Медицинский алфавит. 2020; 33: 26–34. [Vorobyova Yu.D., Diukova G.M. Asthenic syndrome in context of COVID-19 pandemic. Medical alphabet. 2020; 33: 26–34 (in Russian).] 9. Bansal AS, Bradley AS, Bishop KN et al. Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun 2012; 26 (1): 24–31. DOI: 10.1016/j.bbi.2011.06.016 10. Neufeld KJ, Leoutsakos JMS, Yan H et al. Fatigue symptoms during the first year following ARDS. Chest 2020; 158 (3): 999–1007. DOI: 10.1016/j.chest.2020.03.059 11. Sasannejad C, Ely EW, Lahiri S. Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms. Crit Care 2019; 23 (1): 352. DOI: 10.1186/s13054-019-2626-z 12. Sykes DL, Holdsworth L, Jawad N et al. Post-COVID-19 symptom burden: what is Long-COVID and how should we manage it? Lung 2021: 1–7. DOI: 10.1007/s00408-021-00423-z 13. Rauch B, Kern-Matschilles S, Haschka SJ et al. COVID-19-related symptoms 6 months after the infection – Update on a prospective cohort study in Germany. MedRxiv [Preprint] 2021: 10.1101/2021. 02.12.21251619. DOI: 10.1101/2021.02.12.21251619 14. Woo MS, Malsy J, Pöttgen J et al. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun 2020; 2 (2): fcaa205. DOI: 10.1093/braincomms/fcaa205 15. Almeria M, Cejudo JC, Sotoca J et al. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health 2020; 9: 100163. DOI: 10.1016/j.bbih.2020.100163 16. Zhou H, Lu S, Chen J et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res 2020; 129: 98–102. DOI: 10.1016/j.jpsychires.2020.06.022 17. Jacomy H, Fragoso G, Almazan G et al. Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice. Virology 2006; 349 (2): 335–46. DOI: 10.1016/j.virol. 2006.01.049 18. Arbi YM, Harthi A, Hussein J. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection 2015; 43 (4): 495–501. DOI: 10.1007/s15010-015-0720-y 19. Nascimento Conde J, Schutt WR, Gorbunova EE, Mackow ER. Recombinant ACE2 expression is required for SARS-CoV-2 to infect primary human endothelial cells and induce inflammatory and procoagulative responses. MBio 2020; 11 (6): e03185-20. DOI: 10.1128/mBio.03185-20 20. Evans PC, Rainger GE, Mason JC et al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc Res 2020; 116 (14): 2177–84. DOI: 10.1093/cvr/cvaa230 21. Delorme C, Paccoud O, Kas A et al. Covid-19 related encephalopathy: A case series with brain FDG-PET/CT findings. Eur J Neurol 2020; 27 (12): 2651–7. DOI: 10.1111/ene.14478 22. Egbert AR, Cankurtaran S, Karpiak S. Brain abnormalities in COVID-19 acute/subacute phase: A rapid systematic review. Brain Behav Immun 2020; 89: 543–54. DOI: 10.1016/j.bbi.2020.07.014 23. Lee MH, Perl DP, Nair G et al. Microvascular Injury in the Brains of Patients with Covid-19. N Engl J Med 2021; 384 (5): 481–3. DOI: 10.1056/NEJMc2033369 24. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. Published date: 18 December 2020. www.nice.org. uk/guidance/ng188 25. Ткачева О.Н., Котовская Ю.В., Рунихина Н.К. и др. Клинические рекомендации «старческая астения». Российский журнал гериатрической медицины. 2020; 1: 11–46. DOI: 10.37586/2686-8636-1-2020-11-46 [Tkacheva O.N., Kotovskaya Yu.V., Runikhina N.K. et al. Clinical guidelines on frailty. Russian Journal of Geriatric Medicine. 2020; (1): 11–46. DOI: 10.37586/2686-8636-1-2020-11-46 (in Russian).] 26. Xiong J, Lipsitz O, Nasri F et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord 2020; 277: 55–64. DOI: 10.1016/j.jad.2020.08.001 27. Liu N, Zhang F, Wei C et al. Prevalence and predictors of PTSS during COVID-19 outbreak in China hardest-hit areas: Gender differences matter. Psychiatry Res 2020; 287: 112921. DOI: 10.1016/j.psychres.2020.112921 28. Roozbeh F, Saeedi M, Alizadeh-Navaei R et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother 2021; 76 (3): 753–7. DOI: 10.1093/jac/dkaa501 29. Seftel D, Boulware DR. Prospective Cohort of fluvoxamine for early treatment of Coronavirus Disease 19. Open Forum Infect Dis 2021; 8 (2): ofab050. DOI: 10.1093/ofid/ofab050 30. Machicao F, Muresanu DF, Hundsberger H et al. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci 2012; 322 (1–2): 222–7. DOI: 10.1016/j.jns.2012.07.069 31. Fedorovich AA. Non-invasive evaluation of vasomotor and metabolic functions of microvascular endothelium in human skin. Microvasc Res 2012; 84 (1): 86–93. DOI: 10.1016/j.mvr.2012.03.011 32. Федорович А.А., Соболева Г.Н. Коррекция когнитивных нарушений препаратом Актовегин® у пациентов с артериальной гипертензией и ишемической болезнью сердца. Эффективная фармакотерапия 2015; 23: 42–51. [Fedorovich A.A., Soboleva G.N. Correction of cognitive impairments by ActoveginR in patients with arterial hypertension and ischemic heart disease. Effective Pharmacotherapy 2015; 23: 42–51 [(in Russian).] 33. Танашян М.М., Шабалина А.А., Лагода О.В. и др. Мультимодальный подход к коррекции неврологических проявлений хронической ишемии мозга. Терапевтический архив. 2018; 90 (12): 61–7. [Tanashyan M.M., Shabalina A.A., Lagoda O.V. et al. Multimodal approach to treatment of neurological complications of chronic brain ischemia. Terapevticheskii arkhiv. 2018; 90 (12): 61–7 (in Russian).] 34. Коняева В.В. Энцефалопатия, ассоциированная с COVID-19: опыт клинических наблюдений в практической работе невролога. Лечебное дело. 2020; 3: 43–6. DOI: 10.24412/2071-5315-2020-12255 [Konyaeva V.V. Encephalopathy associated with COVID-19: experience of clinical observations in practical work of neurologist. Lechebnoe delo. 2020; 3: 43–6 DOI: 10.24412/2071-5315-2020-12255 (in Russian).] 35. Ковальчук В.В. Роль новой коронавирусной инфекции (COVID-19) в прогрессировании и развитии сосудистых заболеваний головного мозга. Грамотный выбор средств патогенетической терапии – залог успеха лечения и профилактики. Взгляд специалиста из «красной зоны». Неврология, нейропсихиатрия, психосоматика. 2021; 13 (1): 57–66. DOI: 10.14412/2074-2711-2021-1-57-66 [Kovalchuk V.V. The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’. Neurology, Neuropsychiatry, Psychosomatics. 2021; 13 (1): 57–66. DOI: 10.14412/2074-2711-2021-1-57-66 (in Russian).]